drugset / Trial / NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Timeline
- Start
- 2023-08-17
- Primary completion
- 2027-12-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | DB-1310 | Unknown | — | Intravenous |
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |